Appendix cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Appendix cancer}} {{CMG}}; {{AE}} ==Overview== There is no treatment for [disease name]; the mainstay of therapy is supportive care. OR Supportive therapy for [...")
 
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
[[:File:///C:/jb-UTD/contents/mobipreview.htm?40/0/40967?source=see link|capecitabine]] or 5-FU with or without a platinum drug
FOLFOX regimen (5- [[:File:///C:/jb-UTD/contents/mobipreview.htm?32/32/33280?source=see link|fluorouracil]] , [[:File:///C:/jb-UTD/contents/mobipreview.htm?23/54/24423?source=see link|leucovorin]] , and [[:File:///C:/jb-UTD/contents/mobipreview.htm?2/11/2233?source=see link|oxaliplatin]])
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
There is no treatment for [disease name]; the mainstay of therapy is supportive care.


Line 53: Line 57:
===Disease Name===
===Disease Name===


* '''1 Stage 1 - Name of stage'''
*
** 1.1 '''Specific Organ system involved 1'''
 
*** 1.1.1 '''Adult'''
**** '''Modified FOLFOX6''' : Cycle length 14 days
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''  
***** [[drug name|'''Oxaliplatin''']] 85 mg/m <sup>2</sup> IV
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
***** Dilute with 250 mL 5 percent dextrose in water (D5W)
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
***** Administer over 2 hrs
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** ''Avoid extravasation: May cause significant tissue damage''
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** '''Leucovorin''' 400  mg/m <sup>2</sup> IV  (d,l-racemic mixture)  / 200 mg/m <sup>2</sup> IV  (l-leucovorin)
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
***** Dilute with 250 mL D5W
*** 1.1.2 '''Pediatric'''
***** Administer over 2 hrs concurrent with oxaliplatin.
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
***** [[drug name|'''Fluorouracil (FU)''']] 400 mg/m <sup>2</sup> IV bolus
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)   
***** Slow IV push over 5 mins (administer immediately after leucovorin)
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
***** [[drug name|'''Fluorouracil (FU)''']] 2400 mg/m <sup>2</sup> IV
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
***** Administer immediately after FU IV bolus
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Dilute with 500 to 1000 mL D5W
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
***** Administer over 46 hours
****1.1.2.2 (Specific population e.g. '<nowiki/>'''''children < 8 years of age'''''')
*** '''Doses should be recalculated if there is a 10 percent or more change in body weight.'''
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
***  
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
*** In order to decrease chance of developing Oxaliplatin induced neuropathy recommend patients to avoid exposure to cold up to 48 hours after each infusion.
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
*** '''Prior to each treatment'''
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
*** Assess changes in neurologic function
** 1.2 '''Specific Organ system involved 2'''
*** Assess electrolytes and liver and renal function
*** 1.2.1 '''Adult'''
*** CBC with differential and platelet count
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
** '''Diarrhea:'''
*** 1.2.2  '''Pediatric'''
** Grade 2 or worse diarrhea,
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
** Withhold treatment
** Restart at a lower dose of FU after complete resolution
** '''Severe diarrhea, mucositis, and myelosuppression after FU''' <math>\blacktriangledown</math>
** Evaluate for dihydropyrimidine dehydrogenase deficiency


* 2 '''Stage 2 - Name of stage'''
***
** 2.1 '''Specific Organ system involved 1 '''
**
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.1.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.1.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)


==References==
==References==

Revision as of 22:36, 29 January 2019

Appendix cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Differentiating Appendix cancer from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

MRI

CT scan

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Appendix cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Appendix cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Appendix cancer medical therapy

CDC on Appendix cancer medical therapy

Appendix cancer medical therapy in the news

Blogs on Appendix cancer medical therapy

Directions to Hospitals Treating Appendix cancer

Risk calculators and risk factors for Appendix cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

capecitabine or 5-FU with or without a platinum drug

FOLFOX regimen (5- fluorouracil , leucovorin , and oxaliplatin)

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
  • Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
  • Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
  • Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

        • Modified FOLFOX6 : Cycle length 14 days
          • Oxaliplatin 85 mg/m 2 IV
          • Dilute with 250 mL 5 percent dextrose in water (D5W)
          • Administer over 2 hrs
          • Avoid extravasation: May cause significant tissue damage
          • Leucovorin 400 mg/m 2 IV (d,l-racemic mixture) / 200 mg/m 2 IV (l-leucovorin)
          • Dilute with 250 mL D5W
          • Administer over 2 hrs concurrent with oxaliplatin.
          • Fluorouracil (FU) 400 mg/m 2 IV bolus
          • Slow IV push over 5 mins (administer immediately after leucovorin)
          • Fluorouracil (FU) 2400 mg/m 2 IV
          • Administer immediately after FU IV bolus
          • Dilute with 500 to 1000 mL D5W
          • Administer over 46 hours
      • Doses should be recalculated if there is a 10 percent or more change in body weight.
      • In order to decrease chance of developing Oxaliplatin induced neuropathy recommend patients to avoid exposure to cold up to 48 hours after each infusion.
      • Prior to each treatment
      • Assess changes in neurologic function
      • Assess electrolytes and liver and renal function
      • CBC with differential and platelet count
    • Diarrhea:
    • Grade 2 or worse diarrhea,
    • Withhold treatment
    • Restart at a lower dose of FU after complete resolution
    • Severe diarrhea, mucositis, and myelosuppression after FU <math>\blacktriangledown</math>
    • Evaluate for dihydropyrimidine dehydrogenase deficiency

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Appendix_cancer_medical_therapy&oldid=1543214"